OABI — OmniAb, Inc.

Summary of OmniAb, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by increased milestone revenue.
• Full Year 2025 Revenue: $18.7 million, compared to $26.4 million in 2024.
• Net Loss: $14.2 million ($0.11 per share) in Q4 2025, slightly worse than a net loss of $13.1 million ($0.12 per share) in Q4 2024. Full year net loss was $64.8 million ($0.57 per share) compared to $62 million ($0.61 per share) in 2024.
• Operating Expenses: Decreased to $24.1 million in Q4 2025 from $26.7 million in Q4 2024, and full year operating expenses were $87.6 million, down from $100.9 million in 2024.
• Cash Position: Ended 2025 with $54 million in cash and equivalents, with expectations to end 2026 with $30-$35 million.

2. Strategic Updates and Business Highlights

• Partner Growth: Ended 2025 with 107 partners and 407 active programs, a net increase of 44 programs during the year.
• Technology Launches: Introduced OmniUltra, a transgenic chicken platform for antibody development, and expanded the xPloration platform for high-throughput screening.
• Clinical Progress: Achieved significant advancements with 25 programs progressing through various stages, including one entering human clinical trials.
• Milestone Payments: Over $3 billion in total contracted milestone payments across active antibody programs, with an average royalty rate of 3.4%.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $25 million and $30 million, indicating a recovery from 2025 levels.
• Operating Expenses: Projected to be between $80 million and $85 million, with cash operating expenses expected to be $50 million to $55 million.
• Long-Term Outlook: Anticipates a shift towards more royalty-driven revenue as the portfolio matures, with a trajectory towards positive cash flow.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Notable decrease in both quarterly and annual revenue compared to previous years, primarily from license and milestone revenue.
• Net Losses: Continued net losses raise concerns about profitability and cash flow sustainability.
• Market Conditions: Potential headwinds from broader market fundraising activities affecting partner spending and program initiation.
• Program Attrition: Experienced 40 program terminations during the year, which is a natural part of drug development but reflects ongoing challenges in the industry.

5. Notable Q&A Insights

• xPloration Demand: Strong interest from existing high-tier partners, with expectations for significant growth in revenue from the xPloration platform, although specifics on revenue projections were not disclosed.
• OmniUltra Reception: Positive initial response from partners, with expectations for increased program additions as the technology gains traction.
• Cash Flow Breakeven: While no specific timeline was provided, management expressed confidence in reaching cash flow breakeven, driven by advancements in partner programs.
• Royalty Structures: Majority of deals are based on flat royalties, with some tiered structures; management indicated potential for higher royalties with newer technologies.

Overall, while OmniAb has made significant strides in expanding its partner base and technological offerings, it faces challenges related to revenue decline and net losses, with a cautious yet optimistic outlook for 2026 and beyond.